Roche: collaboration with Zealand Pharma
(CercleFinance.com) - Roche announces that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide as a potential pivotal treatment for overweight and obese people.
The agreement enables a range of potentially first-in-class therapeutic options, such as monotherapy and fixed-dose combination with Roche's lead active CT 388, the Swiss healthcare group says.
Under the agreed terms, Zealand Pharma will receive upfront payments of $1.65bn, and will be eligible for development milestone payments of $1.2bn and sales-based milestone payments of $2.4bn.
The deal's completion is subject to regulatory approvals and other customary conditions. The parties expect the transaction to close in Q2 2025.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The agreement enables a range of potentially first-in-class therapeutic options, such as monotherapy and fixed-dose combination with Roche's lead active CT 388, the Swiss healthcare group says.
Under the agreed terms, Zealand Pharma will receive upfront payments of $1.65bn, and will be eligible for development milestone payments of $1.2bn and sales-based milestone payments of $2.4bn.
The deal's completion is subject to regulatory approvals and other customary conditions. The parties expect the transaction to close in Q2 2025.
Copyright (c) 2025 CercleFinance.com. All rights reserved.